Jun 2026 (Q2 FY26) — Jul 30, 2026
Cinemark Q2 FY26 — Historic Records in Revenue, EBITDA, and Free Cash Flow
Read the full callCinemark (CNK) earnings
- Mar 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Cinemark earnings: last reported Thu, 30 Jul 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 643 | +18.9% YoY | Quarterly, as filed | Quarter to Mar 2026 | Revenue from operations as filed. |
| Operating margin | Operating profit / revenue | Quarter to Mar 2026 | Not in the filed figures for the quarter to mar 2026. No older figure is substituted. | ||
| Net profit | -6.4 | Quarterly, as filed | Quarter to Mar 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Guidance
What management said, and what became of it
6 of 7 judged targets kept · 16 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Additional D-BOX motion-seat auditoriums installed | an additional 80 D-BOX auditoriums across 2025 and 2026 | Jun 2025 | In the first half of '26, we already added seven new XDs, 12 new ScreenXs, two new IMAXs with three new 70-millimeter projectors activated and 112 new D-BOX auditoriums. | Achieved |
| Additional ScreenX auditoriums rolled out | 20 more ScreenX experiences by the end of 2026 | Jun 2025 | In the first half of '26, we already added seven new XDs, 12 new ScreenXs, two new IMAXs with three new 70-millimeter projectors activated | On Track |
1 of Cinemark Holdings, Inc.'s 23 targets was missed. See which ones, and which are quietly gone. The 2 above are the free sample; 21 more targets are in the full ledger.
Claimed
- Worldwide revenue exceeded $1 billion for the first time in company history.
- Achieved highest ever quarterly adjusted EBITDA of $294 million.
- Adjusted EBITDA margin reached 27.1%, the second highest quarterly margin in history.
- Generated nearly $300 million of free cash flow.
- Achieved all-time high quarterly admissions revenue, concession sales, and per caps worldwide.
- Domestic market share gains despite high box office capacity.
- Healthy growth of younger audiences (under 25) with frequency up ~20% year-over-year.
Qualified
Price
$39 +1.35% · +$0.52
Performance +47.4% 1Y
1Y: $26.46 on 17 Oct 2025 → $39. High $39 (19 Oct 2026), low $21.93 (18 Dec 2025).
- Previous close
- $38.48
- 52-week range
- $21.93 – $39
- One year
- +46.07%
Overview
- Symbol
- CNK
- Sector
- Communication Services
- Exchange
- US
- Currency
- USD
Guidance
What management said, and what became of it
6 of 7 judged targets kept · 16 open · verdicts reflect calls analysed to Jun 2026.
| Target | Original wording | Said | Latest call | Verdict |
|---|---|---|---|---|
| Additional D-BOX motion-seat auditoriums installed | an additional 80 D-BOX auditoriums across 2025 and 2026 | Jun 2025 | In the first half of '26, we already added seven new XDs, 12 new ScreenXs, two new IMAXs with three new 70-millimeter projectors activated and 112 new D-BOX auditoriums. | Achieved |
| Additional ScreenX auditoriums rolled out | 20 more ScreenX experiences by the end of 2026 | Jun 2025 | In the first half of '26, we already added seven new XDs, 12 new ScreenXs, two new IMAXs with three new 70-millimeter projectors activated | On Track |
Claimed
- Worldwide revenue exceeded $1 billion for the first time in company history.
- Achieved highest ever quarterly adjusted EBITDA of $294 million.
- Adjusted EBITDA margin reached 27.1%, the second highest quarterly margin in history.
- Generated nearly $300 million of free cash flow.
- Achieved all-time high quarterly admissions revenue, concession sales, and per caps worldwide.
- Domestic market share gains despite high box office capacity.
- Healthy growth of younger audiences (under 25) with frequency up ~20% year-over-year.
Qualified
The full ledger
Open Cinemark Holdings, Inc.’s full ledger
A free account opens 5 company ledgers a month. All 23 tracked commitments, with each call’s wording and source.
Call summaries
Mar 2026 (Q1 FY26) — May 1, 2026
Cinemark Q1 FY26 — Strongest Q1 Since Pandemic with Significant Revenue Growth and Margin Expansion
Read the full callEvery analysed call
Cinemark earnings calls (CNK)
Financials
What the filings say
Net profit, year on year: +84% (quarter to mar 2026 against mar 2025).
| Line item | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 734 | 922 | 814 | 541 | 941 | 858 | 776 | 643 |
| Interest | 35 | 37 | 35 | 39 | 39 | 32 | 32 | 35 |
| Net profit | 46 | 188 | 51 | -39 | 94 | 50 | 34 | -6 |
| EPS ($ per share) | 0.37 | 1.54 | — | -0.32 | 0.81 | 0.43 | — | -0.06 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | — | — | — | — |
| Reserves | 639 | 687 | 28 | -389 | — | — | — | — |
| Total liabilities | 3,073 | 4,380 | 4,764 | 4,896 | — | — | — | — |
| Fixed assets | 1,833 | 1,735 | 1,615 | 1,383 | 1,232 | 1,162 | 1,145 | 1,176 |
| Total assets | 4,482 | 5,828 | 5,563 | 5,231 | — | — | — | — |
| Line item | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 |
|---|---|---|---|---|---|---|---|
| Cash from operations | 463 | 529 | 557 | 562 | -330 | 166 | — |
| Cash from investing | -328 | -410 | -451 | -311 | -83 | -89 | — |
| Cash from financing | -164 | -158 | -193 | -187 | 584 | -20 | — |
| Net cash flow | — | -39 | -96 | 62 | 167 | 52 | — |
| Capital expenditure | -327 | -381 | -346 | -304 | -84 | -95 | -111 |
| Free cash flow | 136 | 148 | 211 | 258 | -414 | 71 | — |
CNK revenue by segment
| Segment | Q3 FY2024 | Q4 FY2024 | Q1 FY2025 | Q2 FY2025 | Q3 FY2025 | Q4 FY2025 | Q1 FY2026 | Q2 FY2026 | YoY growth latest quarter |
|---|---|---|---|---|---|---|---|---|---|
| US Reportable | — | — | — | 81% | 80% | 84% | 80% | 79% | +13.3% |
| International Reportable | — | — | — | 19% | 20% | 17% | 20% | 21% | +24.9% |
Share of consolidated revenue by quarter. Q4 is the fiscal year less its first three quarters.
See how segments are shifting across companies → Segment Shift
Revenue by region
Q2 FY2026 · share of revenue
- US 80% ↓ 1 pt
- Other International Countries 13% ↑ 2 pt
- BR 7%
- Geography Eliminations 0%
As CNK cuts its regions in its filings; they can nest, so they need not add to 100%.
Insider filings
77 filings between Nov 7, 2025 and Sep 25, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$5.18M
3 sales by 2 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 24
- Award — granted as compensation
- 25
- Tax withheld — shares kept back by the company to cover tax
Also filed: 18 dispositions to the issuer, 7 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Zoradi Mark | — | $4.43M | May 1, 2026 |
| Thomas Melissa | — | $754.8K | Feb 4, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 25, 2026 | Fernandes Valmir Pr - Cinemark International | Disposition to issuer 10b5-1 plan | 38,000 | $1.44M |
| Sep 11, 2026 | Fernandes Valmir Pr - Cinemark International | Disposition to issuer 10b5-1 plan | 20,000 | $703.4K |
| Sep 1, 2026 | Cavalier Michael EVP-General Counsel | Disposition to issuer 10b5-1 plan | 107,296 | $3.76M |
| Aug 31, 2026 | Gamble Sean Chief Executive Officer | Disposition to issuer 10b5-1 plan | 7,191 | $258.8K |
| Aug 24, 2026 | Gamble Sean Chief Executive Officer | Disposition to issuer 10b5-1 plan | 138,884 | $5.30M |
| Aug 20, 2026 | Thomas Melissa EVP, Chief Financial Officer | Disposition to issuer 10b5-1 plan | 38,236 | $1.43M |
| Aug 12, 2026 | Burian Lawrence J. Director | Award | 3,908 | $0 |
| Jul 28, 2026 | Gierhart Wanda Marie Chief Marketing & Content Ofc | Disposition to issuer 10b5-1 plan | 9,450 | $330.8K |
| Jun 15, 2026 | CHERESKIN BENJAMIN D Director | Award | 5,439 | $0 |
| Jun 15, 2026 | Antonellis Darcy Director | Award | 5,439 | $0 |
| Jun 15, 2026 | Zoradi Mark Director | Award | 5,439 | $0 |
| Jun 15, 2026 | Humrichouse Ximena G Director | Award | 5,439 | $0 |
| Jun 15, 2026 | Sepulveda Carlos M Director | Award | 5,439 | $0 |
| Jun 15, 2026 | ROSENBERG STEVE Director | Award | 5,439 | $0 |
| Jun 15, 2026 | Mitchell Kevin Leroy Director | Award | 5,439 | $0 |
| Jun 15, 2026 | Syufy Raymond W Director | Award | 5,439 | $0 |
| Jun 15, 2026 | Loewe Nancy S. Director | Award | 5,439 | $0 |
| Jun 15, 2026 | SENIOR ENRIQUE Director | Award | 5,439 | $0 |
| Jun 11, 2026 | Fernandes Valmir Pr - Cinemark International | Disposition to issuer | 30,000 | $1.00M |
| Jun 11, 2026 | Humrichouse Ximena G Director | Gift | 3,503 | $0 |
| Jun 10, 2026 | Gierhart Wanda Marie Chief Marketing & Content Ofc | Disposition to issuer 10b5-1 plan | 23,456 | $774.0K |
| Jun 9, 2026 | Gierhart Wanda Marie Chief Marketing & Content Ofc | Disposition to issuer 10b5-1 plan | 23,456 | $750.6K |
| Jun 8, 2026 | Gierhart Wanda Marie Chief Marketing & Content Ofc | Disposition to issuer 10b5-1 plan | 2,769 | $87.2K |
| Jun 4, 2026 | Bedard Caren SVP-Global Controller | Disposition to issuer | 8,000 | $241.8K |
| May 12, 2026 | Thomas Melissa EVP, Chief Financial Officer | Disposition to issuer 10b5-1 plan | 37,784 | $1.00M |
| May 1, 2026 | Zoradi Mark Director | Sale 10b5-1 plan | 150,000 | $4.43M |
| Apr 6, 2026 | Zoradi Mark Director | Gift | 7,364 | $0 |
| Apr 6, 2026 | Gamble Sean Chief Executive Officer | Disposition to issuer 10b5-1 plan | 109,455 | $3.29M |
| Apr 6, 2026 | Gierhart Wanda Marie Chief Marketing & Content Ofc | Disposition to issuer 10b5-1 plan | 11,169 | $335.1K |
| Apr 1, 2026 | Bedard Caren SVP-Global Controller | Award | 700 | $0 |
| Feb 27, 2026 | Thomas Melissa EVP, Chief Financial Officer | Disposition to issuer 10b5-1 plan | 32,396 | $910.0K |
| Feb 27, 2026 | Gamble Sean Chief Executive Officer | Disposition to issuer 10b5-1 plan | 73,206 | $2.02M |
| Feb 21, 2026 | Cavalier Michael EVP-General Counsel | Gift | 82,052 | $0 |
| Feb 21, 2026 | Cavalier Michael EVP-General Counsel | Tax withheld | 2,445 | $64.8K |
| Feb 21, 2026 | Gamble Sean Chief Executive Officer | Tax withheld | 11,791 | $312.3K |
| Feb 21, 2026 | Gamble Sean Chief Executive Officer | Gift | 435,589 | $0 |
| Feb 21, 2026 | Fernandes Valmir Pr - Cinemark International | Gift | 68,256 | $0 |
| Feb 21, 2026 | Thomas Melissa EVP, Chief Financial Officer | Tax withheld 10b5-1 plan | 2,608 | $69.1K |
| Feb 21, 2026 | Fernandes Valmir Pr - Cinemark International | Tax withheld | 2,115 | $56.0K |
| Feb 21, 2026 | Gierhart Wanda Marie Chief Marketing & Content Ofc | Tax withheld 10b5-1 plan | 2,118 | $56.1K |
| Feb 21, 2026 | Bedard Caren SVP-Global Controller | Tax withheld | 428 | $11.3K |
| Feb 20, 2026 | Cavalier Michael EVP-General Counsel | Award | 20,275 | $0 |
| Feb 20, 2026 | Cavalier Michael EVP-General Counsel | Tax withheld | 42,665 | $1.12M |
| Feb 20, 2026 | Cavalier Michael EVP-General Counsel | Tax withheld | 3,761 | $99.1K |
| Feb 20, 2026 | Cavalier Michael EVP-General Counsel | Tax withheld | 4,717 | $124.3K |
| Feb 20, 2026 | Gamble Sean Chief Executive Officer | Award | 108,652 | $0 |
| Feb 20, 2026 | Gamble Sean Chief Executive Officer | Tax withheld | 17,729 | $467.3K |
| Feb 20, 2026 | Gamble Sean Chief Executive Officer | Tax withheld | 23,028 | $607.0K |
| Feb 20, 2026 | Gamble Sean Chief Executive Officer | Disposition to issuer | 207,351 | $5.47M |
| Feb 20, 2026 | Gamble Sean Chief Executive Officer | Award | 554,794 | $14.62M |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Cinemark Holdings, Inc.
Free account. Everything above stays public.
Write why you follow Cinemark Holdings, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading